Drug intelligence / Profile preview

YH0618 (The University of Hong Kong)

Development stage: Unknown
Lead developer: The University of Hong Kong
Administration: Oral

Overview

YH0618 is a Traditional Chinese Medicine (TCM) herbal formula, typically prepared as a soup, developed to mitigate chemotherapy-induced toxicities in cancer patients. It is primarily studied for its potential to reduce side effects such as fatigue, gastrointestinal distress, and myelosuppression following chemotherapy. The formula is administered orally and is designed to align with local dietary habits in regions like Hong Kong. Research into YH0618 has been conducted by the University of Hong Kong to evaluate its efficacy and safety as a supportive care intervention in oncology.

Other names: YH0618 soupYH-0618 soupYH 0618 soupYH0618 formulaYH-0618 formulaYH 0618 formula

Targets

FOXO4 (Forkhead box protein O4)SMAD3 (SMAD family member 3)

Beyond the preview

Go deeper on YH0618 (The University of Hong Kong).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH0618 (The University of Hong Kong).

Explore the full profile